[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cedar Valley Digestive Health Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100551434","phase-2-tenapanor-in-synucleinopathy-related-constipation-100551434",false,"NCT06460038","Tenapanor in Synucleinopathy-Related Constipation","Efficacy and Safety of Tenapanor in Synucleinopathy-Related Constipation","Inclusion Criteria\n\n1. Age 50-89 years.\n2. Diagnosis of PD within Hoehn and Yahr stages 1-3, confirmed by a neurologist per International Parkinson and Movement Disorder Society criteria.\n3. Average weekly stool frequency of ≤5 spontaneous bowel movements (SBMs) and ≤2 complete spontaneous bowel movements (CSBMs) over the past 6 months. These criteria will be verified during a 2-week screening period.\n4. Stool consistency ≤3 on the Bristol Stool Form Scale (BSFS). This criterion will be verified during a 2-week screening period.\n5. Agreement to use contraception, if applicable.\n\nExclusion Criteria\n\n1. Functional diarrhea or IBS-D\u002FM based on Rome IV Criteria.\n2. Symptomatic structural GI abnormalities or inflammatory bowel disease.\n3. Significant hepatic (ALT or AST ≥ 2.5x the upper limit of normal) or renal (serum creatinine \\>2mg\u002Fdl) dysfunction.\n4. Pregnancy or lactation.\n5. Diagnosis of primary dyssynergic defecation by anorectal manometry.","ALL","50 Years","89 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation",[27,28],"Synucleinopathy","Parkinson's Disease",[30,31,32,33],"tenapanor","synucleinopathy","Parkinson's disease","constipation","RECRUITING","2025-02-06",{"date":37,"type":38},"2025-02-10","ACTUAL",{"date":40,"type":38},"2025-01-01",{"date":42,"type":21},"2027-03",{"name":44,"class":45},"Cedar Valley Digestive Health Center","OTHER",""]